A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
Completed
Vertex Pharmaceuticals Incorporated
Phase 1
2012-01-01
The purpose of this study is to evaluate the relative bioavailability, safety, and
tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
Completed
Eisai Inc.
Phase 2
2011-11-01
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic
hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
Terminated
Vertex Pharmaceuticals Incorporated
Phase 3
2011-11-01
The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in
combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV)
(T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC
genotype. The subjects enrolled in this study will have chronic hepatitis C virus (HCV)
infection and will not have cirrhosis of the liver.
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
Completed
Vertex Pharmaceuticals Incorporated
Phase 1
2012-01-01
The purpose of this study is to evaluate the relative bioavailability, safety, and
tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C
Completed
Vertex Pharmaceuticals Incorporated
Phase 2
2012-07-01
The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in
subjects who have chronic hepatitis C and have not received treatment yet.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
